According to @business, Novo Nordisk shares rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly’s older drug Trulicity in a real-world survey of certain U.S. patients; source: Bloomberg, link: https://www.bloomberg.com/news/articles/2025-09-18/novo-rises-after-ozempic-beats-older-lilly-drug-in-survey. The survey outcome was cited as the catalyst for the session’s move, highlighting trading momentum in Novo Nordisk equity on the comparative effectiveness theme; source: Bloomberg. The report did not cite any direct impact on the cryptocurrency market; source: Bloomberg.